MedTrace Logo

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

NCT00943306 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-06-13

Study results available
· View outcomes & findings →

Summary

This was a long term follow on study to assess the continued long term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia.

Conditions

  • Familial Hypercholesterolemia

Interventions

DRUG

lomitapide

5-60 mg po every day

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Marina Cuchel, MD, PhD · University of Pennsylvania

  • Mark Sumeray, MD · Aegerion Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-29
Primary Completion
2012-09-17
Completion
2014-12-01

Countries

  • United States
  • Canada
  • Italy
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943306 on ClinicalTrials.gov